Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8612372 | 0.72 | SMN1; SMN2 (0.48) | GRM5 | |
| SCHEMBL7692556 | 0.70 | — | — | |
| SCHEMBL67456 | 0.69 | — | — | |
| SCHEMBL2301410 | 0.69 | — | — | |
| SCHEMBL103196 | 0.69 | — | — | |
| SCHEMBL586988 | 0.67 | CYP19A1 (0.34) | GRM5 | |
| SCHEMBL20335418 | 0.65 | LMNA (0.32) | GRM5 | |
| SCHEMBL6026542 | 0.64 | KDM1A (0.44) | — | |
| SCHEMBL4008375 | 0.63 | — | — | |
| SCHEMBL14573610 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116284058-A | Sulfur-nitrogen accurate co-doped graphite alkyne and preparation method thereof | 青岛科技大学 | 2023-06-23 | — | — | CN | claimed |
| CN-111900477-A | High-voltage lithium ion battery electrolyte film-forming additive, electrolyte and battery thereof | 松山湖材料实验室 | 2020-11-06 | — | — | CN | claimed |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4717266-A2 | OCTAHYDRO FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics Incorporated (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12421191-B2 | 3-hydroxyoxindole derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2025-09-23 | — | — | US | disclosed |
| EP-4598916-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4598917-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250099457-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-12226412-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20250034140-A1 | OCTAHYDRO FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therpeutics, Inc. (US) | 2025-01-30 | — | — | US | disclosed |
| US-12139486-B2 | Octahydro fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
| US-5843971-A | 1, 1-BIS (heteroazolyl) alkane derivatives and their use as neuroprotective agents | ASTRA AKTIEBOLAG (SE) | 1998-12-01 | — | — | US | disclosed |
| US-5665747-A | TREATING NERVOUS SYSTEM, PSYCHOLOGICAL, AND BRAIN DISORDERS | ASTRA AKTIEBOLAG (SE) | 1997-09-09 | — | — | US | disclosed |
| EP-0765325-A1 | NOVEL 1,1-BIS(HETEROAZOLYL)ALKANE DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE AGENTS | Astra Aktiebolag (SE) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995033747-A1 | NOVEL 1,1-BIS(HETEROAZOLYL)ALKANE DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE AGENTS | ASTRA AKTIEBOLAG (SE) | 1995-12-14 | — | — | WO | disclosed |
| US-5414007-A | Skin disorders | ALLERGAN, INC. (US) | 1995-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | GRM5 407/4885 |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | GRM5 4668/4885 |
| US-20250099457-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, GRIN3A, NR3C2 | GRM5 30/4885 |
| US-20250034140-A1 | OCTAHYDRO FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, NR5A1 | GRM5 39/4885 |
| US-12421191-B2 | 3-hydroxyoxindole derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | GRM5 81/4885 |
| US-12226412-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | NR3C1, GRIN3A, NR3C2 | GRM5 30/4885 |
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | GRM5 256/4885 |
| US-12139486-B2 | Octahydro fused azadecalin glucocorticoid receptor modulators | NR3C1, NR3C2, NR5A1 | GRM5 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.